Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Mersana Therapeutics, Inc. Banner

Mersana Therapeutics, Inc.

MRSN Stock Analysis

Page title

Section title

About Mersana Therapeutics, Inc.

Biotechnology
Healthcare

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc...

Mersana Therapeutics, Inc. Key Metrics

Market Cap
$260M
52 Weeks Low
$1.07
52 Weeks High
$6.28
P/B
30.55x
P/E
-2.46x
P/S
8.69x

Upcoming Events

    MRSN Analyst Forecasts

    ‌
    ‌

    MRSN Financials

    MRSN Income Statement Key Metrics

    • Revenue(TTM)29.94 M
    • Gross Profit(TTM)28.24 M
    • EBITDA(TTM)-106.98 M
    • Net Income(TTM)-104.77 M
    • EPS Diluted(TTM)-0.87

    Decode MRSN's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    MRSN earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of MRSN (0.959) is higher than the average of its peers (-0.038).

    Net Profit Margin vs Peers

    Net profit margin ratio of MRSN (-4.658) is higher than the average of its peers (-48.510).

    MRSN Return on Equity

    See how efficiently MRSN generates profit for it's shareholders.

    -465.18%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of MRSN (-4.652) is lower than the average of its peers (-0.505).

    Return on Equity Growth

    MRSN's Return on Equity has shown poor growth over the past 10 years, increasing by only -31.91%.

    MRSN Revenue Growth

    See how MRSN has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    MRSN's revenue has grown significantly over the past 10 years, increasing by over 15.14%.